Endocrine therapies including tamoxifen, fulvestrant, and aromatase inhibitors are used for the treatment of ER+ breast cancer following surgery, radiation therapy (RT), and/or chemotherapy (3). The gene discussed is ESR1; the disease is breast cancer.